|
12 Jun 2026
|
Wockhardt
|
Deven Choksey
|
1965.20
|
|
1938.00
(1.40%)
|
|
Not Rated
|
|
|
Wockhardt has transformed into an innovation-led pharmaceutical company with a strong pipeline of novel antibiotics, highlighted by the USFDA approval of Zaynich.
|
|
08 Jul 2025
|
Wockhardt
|
Axis Direct
|
1965.20
|
1870.00
|
1657.80
(18.54%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock, with a target price of Rs 1,870/share reflecting 10% upside potential from the CMP.
|
|
31 Jan 2018
|
Wockhardt
|
HDFC Securities
|
1965.20
|
|
804.75
(144.20%)
|
|
Results Update
|
|
|
Wockhardt Ltd Q3FY18 results comment Revenue decreased by 1.66% to Rs. 1005.3 Cr in Q3FY18 when compared to the previous quarter
|
|
23 May 2017
|
Wockhardt
|
HDFC Securities
|
1965.20
|
|
617.45
(218.28%)
|
|
Results Update
|
|
|
Revenue fell by 13.26% to Rs. 863.53 Cr in Q4FY17 when compared to the previous quarter.
|
|
31 Jan 2017
|
Wockhardt
|
HDFC Securities
|
1965.20
|
|
647.30
(203.60%)
|
|
Results Update
|
|
|
Revenue fell by 6.49% to Rs. 995.56 Cr in Q3FY17 when compared to the previous quarter. Also, it decreased by 7.35% when compared with Q3FY16.
|